Filing summary
Period and issuer: Quarterly report for the three and nine months ended September 30, 2012, filed November 8, 2012. The filing identifies the registrant as Rexahn Pharmaceuticals, Inc., a development-stage biopharmaceutical company—not Opus Genetics, Inc. This conflicts with the supplied company metadata and should be verified.
Financial performance and position
| Metric | Q3 2012 | Nine months 2012 | Comparison / position |
|---|---|---|---|
| Revenue | $0 | $0 | No commercial sales; no revenue in comparable 2011 periods. |
| Research and development expense | $1.07 million | $3.13 million | Down 55.1% and 70.2%, respectively, from 2011. |
| General and administrative expense | $0.60 million | $2.07 million | Down 22.5% and 26.3%, respectively. |
| Net loss | $2.99 million | $6.17 million | 2011 comparatives: $1.47 million and $11.73 million. Loss per share was $0.03 and $0.06, versus $0.02 and $0.13. |
| Operating cash flow | Not presented quarterly | $(5.55) million | Cash used was $10.65 million in the comparable 2011 period. |
| Cash and liquidity | Cash $7.38 million; restricted cash $0.22 million; marketable securities $0.10 million at September 30, 2012. | Total: approximately $7.70 million, versus $13.24 million at December 31, 2011. | |
| Debt and liabilities | No debt instruments on the balance sheet; total liabilities $3.24 million. | Warrant liabilities were $1.52 million, up from $0.87 million at year-end. |
No profit or meaningful operating margin was reported because the company had no revenue and incurred operating losses. The quarterly loss increased year over year, partly reflecting a $1.20 million unrealized warrant loss, compared with a $1.87 million unrealized gain in Q3 2011. The nine-month loss narrowed, mainly as research spending fell and the prior-year warrant gain was not repeated to the same extent.
Business developments and outlook
- Management said available cash, restricted cash, and securities were expected to cover minimum planned operating needs through September 30, 2013. It estimated minimum needs over the next 12 months at approximately $7.5 million and also said additional financing would be needed to fund its broader development plan. No assurance of financing was given.
- Planned spending over the next 12 months included approximately $2.0 million for Archexin Phase II development, $1.5 million for RX-3117, RX-5902, and the preclinical pipeline, $3.8 million for general corporate expenses, and $0.22 million for facilities rent.
- Archexin’s Phase IIa pancreatic cancer study reported median survival of 9.1 months among evaluable patients, compared with cited historical survival of 5.65 months for gemcitabine alone. Management was evaluating next steps, including a possible Phase IIb trial beginning in Q1 2013. The comparison was against historical data, not a concurrent control.
- RX-3117 entered an exploratory Phase I study; the company reported oral bioavailability and no adverse events in that study. RX-5902 had an IND application submitted in July 2012 and could enter Phase I in the first half of 2013.
- Serdaxin did not demonstrate efficacy versus placebo in its Phase IIb depression study; the company had not allocated further resources to that indication. Zoraxel’s Phase IIb plans were under review, partly because it shares an active ingredient with Serdaxin.
- Management anticipated continuing losses. Risks included additional financing needs, clinical and regulatory uncertainty, trial delays or unfavorable results, third-party dependence, intellectual-property protection, and potential NYSE AMEX listing compliance issues.
Other material items
Research and development agreements had an estimated $19.05 million total contract value, with $17.94 million paid since inception; agreements could generally be terminated with notice. A $1.0 million KRICT milestone is payable upon specified marketing approval, which had not occurred. The filing reported no legal proceedings and no material change in internal control over financial reporting; management considered disclosure controls effective.
Investor verification priorities
- Confirm the registrant identity: this supplied filing is for Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Verify the reported operating-loss line: the statement of operations appears to show positive $3.36 million for Q3 2011, although expenses and net loss imply a loss; the filing text is internally inconsistent.
- Assess whether the stated cash runway and minimum-needs estimate remain adequate, and whether financing was subsequently obtained.
- Review the clinical evidence and subsequent decisions for Archexin, RX-3117, RX-5902, Serdaxin, and Zoraxel, including the historical-control basis of the Archexin survival comparison.
- Evaluate the effect of warrant remeasurement on reported earnings and potential dilution from outstanding options and warrants.